-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*For medical professionals to read and reference this gold medal not only means "Olympic spirit", but also "anti-cancer spirit"! In this Winter Olympics, 17-year-old Chinese teenager Su Yiming participated in the competition of the men's snowboard slope obstacle skills and the big jumping event.
He was the only child of the Chinese team
.
On February 7, 2022, in the Winter Olympics Snowboard Men's Slope Obstacle Skills Final, Su Yiming successfully won the silver medal, which is also the best result of the Chinese team in the history of this event! Although he regretted not being able to win the gold medal, Su Yiming said that he felt very much about winning the silver medal and being able to stand on the podium with international "great gods" skaters Max Parrot (champion) and Mark McMorris (third runner-up).
Honored
.
Eight days later, Su Yiming moved to the Shougang Ski Jumping Platform and won the gold medal in the men's snowboard jumping final! It is worth mentioning that Max Parrot, who defeated the "Snow God" Su Yiming and won the gold medal in the men's snowboarding men's slope obstacle skill event, is not only the world's number one snowboarder, but also a cancer patient.
survivor
.
Su Yiming embraces idols On Christmas Eve 2018, Max Parrot was diagnosed with Hodgkin lymphoma
.
To fight the cancer, Max Parrot started 12 chemotherapy sessions for 6 months
.
The advent of cancer made him start to fear death and even feel anxious about his future snowboarding career
.
But at the same time, he also brings hope and courage to more patients by documenting his battle with cancer
.
In June 2019, he finished his last chemo
.
Two months after that, he quickly returned to the X Games and won the gold medal in the big platform
.
In an interview with foreign media in the documentary "MAX - Life as a Gold Medal", Max Parrot said: "Through the fight against cancer, I realized how lucky I am to be alive, if I didn't have cancer two years ago , I will not be what I am now
.
" The gold medal that Max Parrot won at the Beijing Winter Olympics not only means "Olympic spirit", but also "anti-cancer spirit", representing the wonderful after Nirvana's rebirth with brilliance
.
Chemotherapy - the only way to fight cancer with thorns Like other cancer patients, Max Parrot also experienced the toxic side effects of chemotherapy such as nausea, vomiting, hair loss, etc.
, and because of these adverse reactions, he had to stop Training, which is undoubtedly a huge blow to his sports career
.
But in the end, chemotherapy brought him hope of survival, which is why he was able to return to the game, allowing us to see the anti-cancer fighters who challenge their limits today
.
The documentary "MAX - Life as a Gold Medal" For most tumor patients, chemotherapy is a difficult road to bypass in the process of anti-tumor treatment, but it is also a road full of thorns
.
Chemotherapy has always had excellent curative effect on various types of tumors, but it also has obvious damage to the normal proliferating cells of the body
.
In the process of receiving anti-tumor therapy, patients may not be defeated by the tumor, but by the related adverse reactions brought about by chemotherapy
.
Chemotherapy drugs target cells that are actively growing
.
In addition to malignant tumor cells, bone marrow hematopoietic stem cells, digestive tract mucosa, skin and its appendages, endometrium, ovary and other organs or tissues are also more active, which is the histological basis for the corresponding adverse reactions caused by chemotherapy drugs
.
In addition to symptoms such as nausea and vomiting, myelosuppression is also one of the most common adverse reactions of continuous chemotherapy.
It can be considered that almost all chemotherapy drugs have myelosuppressive effects, and the difference lies in the severity
.
Myelosuppression after chemotherapy can be divided into chemotherapy-induced neutropenia (CIN) [1], tumor chemotherapy-related anemia (CRA) [2] and chemotherapy-induced thrombocytopenia (CIT) [3]
.
The appearance of myelosuppression will lead to the reduction or delay in the administration of chemotherapy drugs, which will ultimately affect the anti-tumor efficacy
.
How can chemotherapy-induced myelosuppression be prevented from the source? Chemotherapy has always been one of the most effective means of treating cancer, but bone marrow toxicity has always been an unavoidable problem of chemotherapy
.
However, the current level of tumor diagnosis and treatment cannot completely "remove chemotherapy".
In the face of chemotherapy, what ways can we reduce the harm caused by myelosuppression? Faced with the problems of clinical treatment of tumors caused by myelosuppression, the traditional treatments available for myelosuppression in the past are not bone marrow protection in the true sense.
Granulocytes, platelets or erythropoiesis are produced to shorten the duration of myelosuppression and achieve the purpose of alleviating myelosuppression
.
In addition, the above interventions may also cause other side effects, such as bone marrow hematopoietic reserve depletion
.
So, can myelosuppression caused by chemotherapy be prevented from the source? The answer is yes
.
Cyclin-dependent kinases (CDKs) are key kinases involved in cell cycle regulation.
Currently, CDK4/6 inhibitors on the global market can be used to protect bone marrow in addition to anti-tumor
.
Trilaciclib is a potent, selective, and reversible CDK4/6 inhibitor that induces temporary arrest of hematopoietic stem/progenitor cells (HSPCs) and lymphocytes in the G1 phase of the cell cycle, reducing DNA damage and apoptosis after exposure to chemotherapy die [4]
.
It is known that the cell cycle includes interphase (G1 phase, S phase, G2 phase) and division phase (M phase), of which G1 phase is less sensitive to chemotherapeutic drugs, so hematopoietic stem cells and progenitor cells stay in G1 phase for a short time, which can be avoided.
Reduce the adverse reactions of chemotherapy drugs to neutrophils, red blood cells, platelets and other bone marrow cells damage [4]
.
The emergence of Trilaciclib effectively protects the hematopoietic function of the bone marrow from the source, reduces the incidence and duration of side effects such as myelosuppression, and protects patients during chemotherapy
.
In the future, Trilaciclib is expected to cover domestic patients.
In February 2021, Trilaciclib was approved by the U.
S.
Food and Drug Administration (FDA) for the prevention of myelosuppression caused by chemotherapy in small cell lung cancer (SCLC) [5]
.
Three foreign randomized controlled clinical trials of Trilaciclib for extensive-stage SCLC, G1T28-02 [6], G1T28-03 (NCT02514447) [7], G1T28-05 (NCT03041311) [8-9], showed that severe neutral The duration of neutropenia was shortened by about 4 days, the incidence of severe neutropenia decreased from 52.
9% to 11.
4%, the incidence of grade 3/4 anemia decreased from 31.
9% to 20.
3%, and the incidence of grade 3/4 thrombocytopenia dropped from 36.
1% to 19.
5%
.
More importantly, Trilaciclib does not affect the efficacy of chemotherapy and survival of patients while forming multi-lineage bone marrow protection in SCLC patients, which eliminates the concerns of clinicians that the application of CDK4/6 inhibitors may affect the efficacy of chemotherapy
.
Trilaciclib reduces the incidence of multi-cell lineage myelosuppression in 1-3L SCLC In April 2021, a phase III clinical study of trilaciclib in patients with extensive-stage SCLC receiving carboplatin combined with etoposide or topotecan was conducted in the clinic Trial registration and information publicity platform registration
.
The clinical research based on the Chinese patient population has been carried out, and it is expected to obtain excellent data, so that it can be approved for marketing in China as soon as possible, saving more patients from the pain and trouble of myelosuppression
.
Fighting cancer is a hard road, and the desperation and pressure to face are indescribable, but the experience of Olympic champion Max Parrot tells us that cancer is not invincible, and chemotherapy is not so terrible! In recent years, with the development of new drug research, the adverse reactions caused by chemotherapy are gradually being controlled, and the lives of patients are further guaranteed
.
The documentary "MAX - Life as a Gold Medal" is as Max Parrot said, "Even if I don't know if the treatment is effective, I never give the cancer a chance to beat me
.
"Hope that more patients can overcome cancer as soon as possible and compose the wonderful life in their own life! References: [1] Shi Yanxia, Xing Praseodymium, Zhang Jun, Shen Bo.
Expert consensus on the diagnosis and treatment of neutropenia caused by tumor chemotherapy (2019) Chinese Journal of Oncology, 2019, 46(17): 876-882.
[2] Shi Yanxia, Xing Praseodymium, Zhang Jun, Shen Bo.
Expert consensus on the diagnosis and treatment of anemia related to cancer chemotherapy in China (2019 edition) [J].
China Clinical Oncology, 2019, 46(17): 869-875.
[3] Chinese Society of Clinical Oncology Consensus Expert Committee on Thrombocytopenia Induced by Tumor Chemotherapy.
Chinese Expert Consensus on Diagnosis and Treatment of Thrombocytopenia Induced by Tumor Chemotherapy (2018 Edition)[J ].
Chinese Journal of Oncology, 2018, 40(9): 714-720.
[4] Li Hongdou, Xing Konglang, Chai Fang, et al.
Trilaciclib, a myeloprotective drug for small cell lung cancer patients undergoing chemotherapy[J].
Journal of Clinical Drug Therapy, 2021, 19(10):5.
[5]FDA.
FDA approves drugs to reduce bone marrow suppression caused by chemotherapy［EB/OL］.
（2021-02-12）［2021-02- 14］.
[6]NIH .
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in combination with etoposide and carboplatin in extensive stage small cell lung cancer (SCLC) [EB/OL].
(2020-08-21) [2021-02-18].
[7]Hart LL, Ferrarotto R, Andric ZG, et al.
Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase Ⅱ study［J］.
Adv Ther, 2021, 38(1): 350-365.
[8] Daniel D, Kuchava V, Bondarenko I, et al.
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre , randomised, double-blind, placebo-controlled Phase Ⅱ trial［J］.
Int J Cancer, 2020, 148(10): 2557-2570.
[9] NIH.
Carboplatin, etoposide, and atezolizumab with or without trilaciclib (G1T28) , a CDK 4/6 inhibitor, in extensive stage small cell lung cancer (SCLC) [EB/OL].
(2021-01-27) [2021-02-20].
*This article is only for providing scientific information to medical professionals Information does not represent the views of this platformCarboplatin, etoposide, and atezolizumab with or without trilaciclib (G1T28), a CDK 4/6 inhibitor, in extensive stage small cell lung cancer (SCLC) [EB/OL].
(2021-01-27) [2021-02-20 ].
*This article is only used to provide scientific information to medical professionals and does not represent the views of this platformCarboplatin, etoposide, and atezolizumab with or without trilaciclib (G1T28), a CDK 4/6 inhibitor, in extensive stage small cell lung cancer (SCLC) [EB/OL].
(2021-01-27) [2021-02-20 ].
*This article is only used to provide scientific information to medical professionals and does not represent the views of this platform
He was the only child of the Chinese team
.
On February 7, 2022, in the Winter Olympics Snowboard Men's Slope Obstacle Skills Final, Su Yiming successfully won the silver medal, which is also the best result of the Chinese team in the history of this event! Although he regretted not being able to win the gold medal, Su Yiming said that he felt very much about winning the silver medal and being able to stand on the podium with international "great gods" skaters Max Parrot (champion) and Mark McMorris (third runner-up).
Honored
.
Eight days later, Su Yiming moved to the Shougang Ski Jumping Platform and won the gold medal in the men's snowboard jumping final! It is worth mentioning that Max Parrot, who defeated the "Snow God" Su Yiming and won the gold medal in the men's snowboarding men's slope obstacle skill event, is not only the world's number one snowboarder, but also a cancer patient.
survivor
.
Su Yiming embraces idols On Christmas Eve 2018, Max Parrot was diagnosed with Hodgkin lymphoma
.
To fight the cancer, Max Parrot started 12 chemotherapy sessions for 6 months
.
The advent of cancer made him start to fear death and even feel anxious about his future snowboarding career
.
But at the same time, he also brings hope and courage to more patients by documenting his battle with cancer
.
In June 2019, he finished his last chemo
.
Two months after that, he quickly returned to the X Games and won the gold medal in the big platform
.
In an interview with foreign media in the documentary "MAX - Life as a Gold Medal", Max Parrot said: "Through the fight against cancer, I realized how lucky I am to be alive, if I didn't have cancer two years ago , I will not be what I am now
.
" The gold medal that Max Parrot won at the Beijing Winter Olympics not only means "Olympic spirit", but also "anti-cancer spirit", representing the wonderful after Nirvana's rebirth with brilliance
.
Chemotherapy - the only way to fight cancer with thorns Like other cancer patients, Max Parrot also experienced the toxic side effects of chemotherapy such as nausea, vomiting, hair loss, etc.
, and because of these adverse reactions, he had to stop Training, which is undoubtedly a huge blow to his sports career
.
But in the end, chemotherapy brought him hope of survival, which is why he was able to return to the game, allowing us to see the anti-cancer fighters who challenge their limits today
.
The documentary "MAX - Life as a Gold Medal" For most tumor patients, chemotherapy is a difficult road to bypass in the process of anti-tumor treatment, but it is also a road full of thorns
.
Chemotherapy has always had excellent curative effect on various types of tumors, but it also has obvious damage to the normal proliferating cells of the body
.
In the process of receiving anti-tumor therapy, patients may not be defeated by the tumor, but by the related adverse reactions brought about by chemotherapy
.
Chemotherapy drugs target cells that are actively growing
.
In addition to malignant tumor cells, bone marrow hematopoietic stem cells, digestive tract mucosa, skin and its appendages, endometrium, ovary and other organs or tissues are also more active, which is the histological basis for the corresponding adverse reactions caused by chemotherapy drugs
.
In addition to symptoms such as nausea and vomiting, myelosuppression is also one of the most common adverse reactions of continuous chemotherapy.
It can be considered that almost all chemotherapy drugs have myelosuppressive effects, and the difference lies in the severity
.
Myelosuppression after chemotherapy can be divided into chemotherapy-induced neutropenia (CIN) [1], tumor chemotherapy-related anemia (CRA) [2] and chemotherapy-induced thrombocytopenia (CIT) [3]
.
The appearance of myelosuppression will lead to the reduction or delay in the administration of chemotherapy drugs, which will ultimately affect the anti-tumor efficacy
.
How can chemotherapy-induced myelosuppression be prevented from the source? Chemotherapy has always been one of the most effective means of treating cancer, but bone marrow toxicity has always been an unavoidable problem of chemotherapy
.
However, the current level of tumor diagnosis and treatment cannot completely "remove chemotherapy".
In the face of chemotherapy, what ways can we reduce the harm caused by myelosuppression? Faced with the problems of clinical treatment of tumors caused by myelosuppression, the traditional treatments available for myelosuppression in the past are not bone marrow protection in the true sense.
Granulocytes, platelets or erythropoiesis are produced to shorten the duration of myelosuppression and achieve the purpose of alleviating myelosuppression
.
In addition, the above interventions may also cause other side effects, such as bone marrow hematopoietic reserve depletion
.
So, can myelosuppression caused by chemotherapy be prevented from the source? The answer is yes
.
Cyclin-dependent kinases (CDKs) are key kinases involved in cell cycle regulation.
Currently, CDK4/6 inhibitors on the global market can be used to protect bone marrow in addition to anti-tumor
.
Trilaciclib is a potent, selective, and reversible CDK4/6 inhibitor that induces temporary arrest of hematopoietic stem/progenitor cells (HSPCs) and lymphocytes in the G1 phase of the cell cycle, reducing DNA damage and apoptosis after exposure to chemotherapy die [4]
.
It is known that the cell cycle includes interphase (G1 phase, S phase, G2 phase) and division phase (M phase), of which G1 phase is less sensitive to chemotherapeutic drugs, so hematopoietic stem cells and progenitor cells stay in G1 phase for a short time, which can be avoided.
Reduce the adverse reactions of chemotherapy drugs to neutrophils, red blood cells, platelets and other bone marrow cells damage [4]
.
The emergence of Trilaciclib effectively protects the hematopoietic function of the bone marrow from the source, reduces the incidence and duration of side effects such as myelosuppression, and protects patients during chemotherapy
.
In the future, Trilaciclib is expected to cover domestic patients.
In February 2021, Trilaciclib was approved by the U.
S.
Food and Drug Administration (FDA) for the prevention of myelosuppression caused by chemotherapy in small cell lung cancer (SCLC) [5]
.
Three foreign randomized controlled clinical trials of Trilaciclib for extensive-stage SCLC, G1T28-02 [6], G1T28-03 (NCT02514447) [7], G1T28-05 (NCT03041311) [8-9], showed that severe neutral The duration of neutropenia was shortened by about 4 days, the incidence of severe neutropenia decreased from 52.
9% to 11.
4%, the incidence of grade 3/4 anemia decreased from 31.
9% to 20.
3%, and the incidence of grade 3/4 thrombocytopenia dropped from 36.
1% to 19.
5%
.
More importantly, Trilaciclib does not affect the efficacy of chemotherapy and survival of patients while forming multi-lineage bone marrow protection in SCLC patients, which eliminates the concerns of clinicians that the application of CDK4/6 inhibitors may affect the efficacy of chemotherapy
.
Trilaciclib reduces the incidence of multi-cell lineage myelosuppression in 1-3L SCLC In April 2021, a phase III clinical study of trilaciclib in patients with extensive-stage SCLC receiving carboplatin combined with etoposide or topotecan was conducted in the clinic Trial registration and information publicity platform registration
.
The clinical research based on the Chinese patient population has been carried out, and it is expected to obtain excellent data, so that it can be approved for marketing in China as soon as possible, saving more patients from the pain and trouble of myelosuppression
.
Fighting cancer is a hard road, and the desperation and pressure to face are indescribable, but the experience of Olympic champion Max Parrot tells us that cancer is not invincible, and chemotherapy is not so terrible! In recent years, with the development of new drug research, the adverse reactions caused by chemotherapy are gradually being controlled, and the lives of patients are further guaranteed
.
The documentary "MAX - Life as a Gold Medal" is as Max Parrot said, "Even if I don't know if the treatment is effective, I never give the cancer a chance to beat me
.
"Hope that more patients can overcome cancer as soon as possible and compose the wonderful life in their own life! References: [1] Shi Yanxia, Xing Praseodymium, Zhang Jun, Shen Bo.
Expert consensus on the diagnosis and treatment of neutropenia caused by tumor chemotherapy (2019) Chinese Journal of Oncology, 2019, 46(17): 876-882.
[2] Shi Yanxia, Xing Praseodymium, Zhang Jun, Shen Bo.
Expert consensus on the diagnosis and treatment of anemia related to cancer chemotherapy in China (2019 edition) [J].
China Clinical Oncology, 2019, 46(17): 869-875.
[3] Chinese Society of Clinical Oncology Consensus Expert Committee on Thrombocytopenia Induced by Tumor Chemotherapy.
Chinese Expert Consensus on Diagnosis and Treatment of Thrombocytopenia Induced by Tumor Chemotherapy (2018 Edition)[J ].
Chinese Journal of Oncology, 2018, 40(9): 714-720.
[4] Li Hongdou, Xing Konglang, Chai Fang, et al.
Trilaciclib, a myeloprotective drug for small cell lung cancer patients undergoing chemotherapy[J].
Journal of Clinical Drug Therapy, 2021, 19(10):5.
[5]FDA.
FDA approves drugs to reduce bone marrow suppression caused by chemotherapy［EB/OL］.
（2021-02-12）［2021-02- 14］.
[6]NIH .
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in combination with etoposide and carboplatin in extensive stage small cell lung cancer (SCLC) [EB/OL].
(2020-08-21) [2021-02-18].
[7]Hart LL, Ferrarotto R, Andric ZG, et al.
Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase Ⅱ study［J］.
Adv Ther, 2021, 38(1): 350-365.
[8] Daniel D, Kuchava V, Bondarenko I, et al.
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre , randomised, double-blind, placebo-controlled Phase Ⅱ trial［J］.
Int J Cancer, 2020, 148(10): 2557-2570.
[9] NIH.
Carboplatin, etoposide, and atezolizumab with or without trilaciclib (G1T28) , a CDK 4/6 inhibitor, in extensive stage small cell lung cancer (SCLC) [EB/OL].
(2021-01-27) [2021-02-20].
*This article is only for providing scientific information to medical professionals Information does not represent the views of this platformCarboplatin, etoposide, and atezolizumab with or without trilaciclib (G1T28), a CDK 4/6 inhibitor, in extensive stage small cell lung cancer (SCLC) [EB/OL].
(2021-01-27) [2021-02-20 ].
*This article is only used to provide scientific information to medical professionals and does not represent the views of this platformCarboplatin, etoposide, and atezolizumab with or without trilaciclib (G1T28), a CDK 4/6 inhibitor, in extensive stage small cell lung cancer (SCLC) [EB/OL].
(2021-01-27) [2021-02-20 ].
*This article is only used to provide scientific information to medical professionals and does not represent the views of this platform
